2-氨基-1-(4-甲氧基苄基)-4,5,6,7-四氢-1H-吲哚-3-甲腈 | 113772-12-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 2-氨基-1-(4-甲氧基苄基)-4,5,6,7-四氢-1H-吲哚-3-甲腈
• 英文名称: 2-amino-1-(4-methoxybenzyl)-4,5,6,7-tetrahydroindole-3-carbonitrile
• 英文别名: 2-amino-1-(4-methoxybenzyl)-4,5,6,7-tetrahydro-1H-indole-3-carbonitrile；2-amino-1-[(4-methoxyphenyl)methyl]-4,5,6,7-tetrahydroindole-3-carbonitrile
• CAS: 113772-12-6
• 化学式: C₁₇H₁₉N₃O
• 分子量: 281.357
• InChiKey: HMITZZIOYJRWFM-UHFFFAOYSA-N

物化性质

• 熔点：
  130-132°C
• 沸点：
  516.8±50.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  64
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-氨基-1-(4-甲氧基苄基)-4,5,6,7-四氢-1H-吲哚-3-甲腈 在 硫酸 、 sodium hydride 、 对甲苯磺酸 、 苯甲醚 、 三氟乙酸 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 甲苯 为溶剂， 反应 21.5h， 生成 methyl 4-amino-2,9-dimethyl-9H-pyrido<2,3-b>indole-3-carboxylate
  参考文献：
  名称：

  Forbes, Ian T.; Johnson, Christopher N.; Thompson, Mervyn, Journal of the Chemical Society. Perkin transactions I, 1992, # 2, p. 275 - 282

  摘要：

  DOI：
• 作为产物：
  描述：

  4-甲氧基苄胺 、 2-羟基环己酮二聚物 、 丙二腈 生成 2-氨基-1-(4-甲氧基苄基)-4,5,6,7-四氢-1H-吲哚-3-甲腈
  参考文献：
  名称：

  Forbes, Ian T.; Johnson, Christopher N.; Thompson, Mervyn, Journal of the Chemical Society. Perkin transactions I, 1992, # 2, p. 275 - 282

  摘要：

  DOI：

文献信息

• 9H-pyrido[2,B-8]indole-3-carboxylic acid ester compounds having useful
  申请人：Beecham Group p.l.c.

  公开号：US04952584A1

  公开（公告）日：1990-08-28

  A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, phenyl or phenyl C.sub.1-4 alkyl wherein the phenyl moiety is optionally substituted by one or more C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, hydroxy, C.sub.2-7 alkanoyl, halo, trifluoromethyl, nitro, amino optionally substituted by one or two C.sub.1-6 alkyl groups or by C.sub.2-7 alkanoyl, cyano, carbamoyl or carboxy groups; R.sub.2, R.sub.3 and R.sub.4 are independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylthio, hydroxy, C.sub.2-7 alkanoyl, chloro, fluoro, trifluoromethyl, nitro, amino optionally substituted by one or two C.sub.1-6 alkyl groups or by C.sub.2-7 alkanoyl, cyano, carbamoyl and carboxy, and phenyl, phenyl C.sub.1-4 alkyl or phenyl C.sub.1-4 alkoxy in which any phenyl moiety is optionally substituted by any of these groups; R.sub.5 and R.sub.6 are independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkyl-C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.1-7 alkanoyl, C.sub.1-6 alkylsulphonyl, di-(C.sub.1-6 alkyl)amino C.sub.1-6 alkyl, 3-oxobutyl, 3-hydroxybutyl, phenyl, phenyl C.sub.1-4 alkyl, benzoyl, phenyl C.sub.2-7 alkanoyl or benzenesulphonyl any of which phenyl moieties are optionally substituted by one or two halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, CF.sub.3, amino or carboxy, or R.sub.5 and R.sub.6 together are C.sub.2-6 polymethylene optionally interrupted by oxygen or NR.sub.9 wherein R.sub.9 is hydrogen or C.sub.1-6 alkyl optionally substituted by hydroxy; R.sub.7 is hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkyl-C.sub.1-4 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl; and --CO.sub.2 R.sub.8 is a pharmaceutically acceptable ester group, processes for its preparation and its use for the treatment or prophylaxis of anxiety or depression.

  化合物式（I）或其药学上可接受的盐：##STR1## 其中：R.sub.1是氢、C.sub.1-6烷基、苯基或苯基C.sub.1-4烷基，其中苯基部分可选择性地被一个或多个C.sub.1-6烷基、C.sub.1-6烷氧基、C.sub.1-6烷基硫基、羟基、C.sub.2-7烷酰基、卤、三氟甲基、硝基、氨基（可选择性地被一个或两个C.sub.1-6烷基或C.sub.2-7烷酰基取代）、氰基、氨基甲酰基或羧基取代；R.sub.2、R.sub.3和R.sub.4独立选择自氢、C.sub.1-6烷基、C.sub.1-6烷氧基、C.sub.1-6烷氧羰基、C.sub.1-6烷基硫基、羟基、C.sub.2-7烷酰基、氯、氟、三氟甲基、硝基、氨基（可选择性地被一个或两个C.sub.1-6烷基或C.sub.2-7烷酰基取代）、氰基、氨基甲酰基和羧基、苯基、苯基C.sub.1-4烷基或苯基C.sub.1-4烷氧基，其中任何苯基部分可选择性地被任何这些基团之一取代；R.sub.5和R.sub.6独立选择自氢、C.sub.1-6烷基、C.sub.3-7环烷基、C.sub.3-7环烷基-C.sub.1-4烷基、C.sub.2-6烯基、C.sub.1-7烷酰基、C.sub.1-6烷基磺酰基、二-(C.sub.1-6烷基)氨基C.sub.1-6烷基、3-氧代丁基、3-羟基丁基、苯基、苯基C.sub.1-4烷基、苯甲酰基、苯基C.sub.2-7烷酰基或苯磺酰基，其中任何苯基部分可选择性地被一个或两个卤、C.sub.1-6烷基、C.sub.1-6烷氧基、CF.sub.3、氨基或羧基取代，或R.sub.5和R.sub.6一起是C.sub.2-6聚亚甲基，可选择性地被氧或NR.sub.9中断，其中R.sub.9是氢或C.sub.1-6烷基，可选择性地被羟基取代；R.sub.7是氢、C.sub.1-6烷基、C.sub.3-6环烷基、C.sub.3-6环烷基-C.sub.1-4烷基、C.sub.2-6烯基或C.sub.2-6炔基；和--CO.sub.2R.sub.8是药学上可接受的酯基，其制备方法及其用于治疗或预防焦虑或抑郁症的用途。
• AKT protein kinase inhibitors
  申请人：Mitchell S. Ian

  公开号：US20050130954A1

  公开（公告）日：2005-06-16

  The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供化合物，包括已解决的对映体、二对映异构体、溶剂化物和药学上可接受的盐，其包括公式：A-L-CR，其中CR是一个环核心基团，L是一个连接基团，A如此处所定义。同时提供了使用本发明化合物作为AKT蛋白激酶抑制剂和用于治疗增殖性疾病如癌症的方法。
• AKT PROTEIN KINASE INHIBITORS
  申请人：Mitchell Ian S.

  公开号：US20100168123A1

  公开（公告）日：2010-07-01

  The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供了化合物，包括已分离的对映体、非对映异构体、溶剂化物和药学上可接受的盐，其包括式子：A-L-CR，其中CR是一个环状核心基团，L是一个连接基团，A如上所定义。本发明还提供了使用这些化合物作为AKT蛋白激酶抑制剂和治疗增殖性疾病，如癌症的方法。
• Pyrido[2,3-b]indoles
  申请人：BEECHAM GROUP PLC

  公开号：EP0249301A1

  公开（公告）日：1987-12-16

  A compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R, is hydrogen, C1-6 alkyl, phenyl or phenyl C1-4 alkyl wherein the phenyl moiety is optionally substituted by one or more C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, hydroxy, C2-7 alkanoyl, halo, trifluoromethyl, nitro, amino optionally substituted by one or two C1-6 alkyl groups or by C2-7 alkanoyl, cyano, carbamoyl or carboxy groups; R2, R3 and R4 are independently selected from hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 alkylthio, hydroxy, C2-7 alkanoyl, chloro, fluoro, trifluoromethyl, nitro, amino optionally substituted by one or two C1-6 alkyl groups or by C2-7 alkanoyl, cyano, carbamoyl and carboxy, and phenyl, phenyl C1-4 alkyl or phenyl C1-4, alkoxy in which any phenyl moiety is optionally substituted by any of these groups; R5 and R6 are independently selected from hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, C2-6 alkenyl, C1-7 alkanoyl, C1-6 alkylsulphonyl, di-(C1-6 alkyl)amino C1-6 alkyl, 3-oxobutyl, 3-hydroxybutyl, phenyl, phenyl C1-4 alkyl, benzoyl, phenyl C2-7 alkanoyl or benzenesulphonyl any of which phenyl moieties are optionally substituted by one or two halogen, C1-6 alkyl, C1-8 alkoxy, CF3, amino or carboxy, or R6 and R6 together are C2-6 polymethylene optionally interrupted by oxygen or NR9 wherein R9 is hydrogen or C1-6 alkyl optionally substituted by hydroxy; R7 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-4 alkyl, C2-6 alkenyl or C2-6 alkynyl; and -CO2R8 is a pharamaceutically acceptable ester group, processes for its preparation and its use as a pharmaceutical.

  式 (I) 的化合物或其药学上可接受的盐： 其中 R，是氢、C1-6 烷基、苯基或苯基 C1-4 烷基，其中苯基任选被一个或多个 C1-6 烷基、C1-6 烷氧基、C1-6 烷硫基、羟基、C2-7 烷酰基、卤代、三氟甲基、硝基、任选被一个或两个 C1-6 烷基或 C2-7 烷酰基取代的氨基、氰基、氨基甲酰基或羧基取代； R2、R3 和 R4 独立选自氢、C1-6 烷基、C1-6 烷氧基、C1-6 烷氧羰基、C1-6 硫代烷基、羟基、C2-7 烷酰基、氯、氟、三氟甲基、硝基、任选被一个或两个 C1-6 烷基或 C2-7 烷酰基、氰基、氨基甲酰基和羧基取代的氨基，以及苯基、苯基 C1-4 烷基或苯基 C1-4 烷氧基，其中任何苯基分子任选被上述任一基团取代； 苯基、苯基 C1-4 烷基、苯甲酰基、苯基 C2-7 烷酰基或苯磺酰基，其中任何苯基可选择被一个或两个卤素、C1-6 烷基、C1-8 烷氧基、CF3、氨基或羧基取代，或 R6 和 R6 合在一起是可选择被氧或 NR9 中断的 C2-6 聚亚甲基，其中 R9 是氢或可选择被羟基取代的 C1-6 烷基； R7是氢、C1-6烷基、C3-6环烷基、C3-6环烷基-C1-4烷基、C2-6烯基或C2-6炔基；和 -CO2R8是法学上可接受的酯基，其制备工艺和作为药物的用途。
• Quinindolinone derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
  申请人：BEECHAM GROUP PLC

  公开号：EP0372962B1

  公开（公告）日：1994-07-20